iPPI-DB

Inhibitors of Protein-Protein Interaction Database

Compound 1881

Identifiers

  • Canonical SMILES: 
    CCS(=O)(=O)Nc1ccc(Oc2ccc(F)cc2)c(c1)-c1cn(C)c2c1cc[nH]c2=O
  • IUPAC name: 
    N-[4-(4-fluorophenoxy)-3-{1-methyl-7-oxo-1H,6H,7H-pyrrolo[2,3-c]pyridin-3-yl}phenyl]ethane-1-sulfonamide
  • InChi: 
    InChI=1S/C22H20FN3O4S/c1-3-31(28,29)25-15-6-9-20(30-16-7-4-14(23)5-8-16)18(12-15)19-13-26(2)21-17(19)10-11-24-22(21)27/h4-13,25H,3H2,1-2H3,(H,24,27)
  • InChiKey: 
    AITMUTNEKRWIEC-UHFFFAOYSA-N

External links


86287755
CHEMBL4064089
87G

External search

Bibliography (1)

Publication Name
Hasvold Lisa A., Sheppard George S., Wang Le, Fidanze Steven D., Liu Dachun, Pratt John K., Mantei Robert A., Wada Carol K., Hubbard Robbert, Shen Yu, Lin Xiaoyu, Huang Xiaoli, Warder Scott E., Wilcox Denise, Li Leiming, Buchanan F. Greg, Smithee Lauren, Albert Daniel H., Magoc Terrance J., Park Chang H., Petros Andrew M., Panchal Sanjay C., Sun Chaohong, Kovar Peter, Soni Nirupama B., Elmore Steven W., Kati Warren M., McDaniel Keith F.. . Methylpyrrole inhibitors of BET bromodomains Bioorganic & Medicinal Chemistry Letters. 39

Pharmacological data

Biochemical tests Cellular tests PK tests Cytotoxicity tests
1 2 2 0

Targets

PPI family Best activity Diseases MMoA
Bromodomain / Histone 8.26 cancer Inhibition
Physicochemical filters
Descriptor Lipinski's RO5 Veber Pfizer's 3/75
Compliance
MW 441.12 g/mol
HBA 7
HBD 2
HBA + HBD 9
AlogP 2.72
TPSA 89.43
RB 5
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources Biochemical tests Cellular tests PK tests Cytotoxicity tests
1 1 2 2 0
Pharmacological data
Bibliography Name Target Competition Assay type Assay name Cell line Activity type Activity
10.1016/j.bmcl.2017.02.057 39 BRD4
O60885 		H4
P62805 		Biochemical assay Time-Resolved FRET pKi (inhibition constant, -log10) 8.26
10.1016/j.bmcl.2017.02.057 39 BRD4
O60885 		H4
P62805 		Cellular assay MX-1 proliferation assay MX-1 pEC50 (half maximal effective concentration, -log10) 7.68
10.1016/j.bmcl.2017.02.057 39 BRD4
O60885 		H4
P62805 		Cellular assay Luciferase reporter H1299 pEC50 (half maximal effective concentration, -log10) 7.33
PK data
Bibliography Name Assay name Administration mode Dose (mg/kg) Dose interval (hours) Tolerated AUC Clearance Cmax Oral bioavailability T1/2 (min) Tmax (min) Volume distribution (Vd)
10.1016/j.bmcl.2017.02.057 39 Mouse PK IV IV 3.00 None yes no yes no 33 336 None no
10.1016/j.bmcl.2017.02.057 39 Mouse PK PO PO 10.00 None yes yes no no 33 None None no
Ta Structure Name Drugbank ID
0.5288 Dasabuvir DB09183
0.4403 Merestinib DB12381
0.4348 ABT-072 DB15156
0.4316 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE DB08350
0.4286 N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide DB07000
0.4215 Omipalisib DB12703
0.4110 Vemurafenib DB08881
0.4086 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol DB06898
0.4064 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide DB06896
0.3989 Ponazuril DB11452
0.3959 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one DB07528
0.3959 Dactolisib DB11651
0.3907 Voxtalisib DB12400
0.3889 (13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE DB06888
0.3886 BMS-986158 DB15435